Lyon, France, September 9, 2022 – Centre Léon Bérard (CLB), a Comprehensive Cancer Center in Lyon and Rhône-Alpes has joined the TriNetX global health research network. The TriNetX Network is comprised of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies across the world.

“Centre Léon Bérard is an innovation-driven, global leader dedicated to the fight against cancer,” said Steve Lethbridge, Senior Vice President of Global Healthcare Partnerships at TriNetX. “We are thrilled to welcome CLB to the TriNetX Network and are pleased to support CLB’s strategy to improve access to therapeutic innovations for its patients.”

Each year, more than 2,000 patients from CLB, nearly 23% of its active patient population are included in clinical trials, providing these patients with access to new therapeutic strategies. In 2021, 286 trials, including 52 promoted by CLB itself, were open for enrollment.

“One of Centre Léon Bérard’s strategic priorities is to facilitate access to innovation for cancer patients. This is possible thanks to the dynamism of our Clinical Research and Innovation Department, that helps our patients benefit from therapeutic trials. The objectives of the TriNetX Network are also to broaden this access to patients regardless of their country of origin, which is why we joined the network,” said Professor Jean-Yves Blay, Executive Director, Medical Oncologist, Researcher, and internationally recognized expert in the management of sarcomas, at Centre Léon Bérard.

More than 120 people work within the CLB’s Clinical Research and Innovation Department in conjunction with doctors, pharmacists and nurses, but also with technical and medical platforms (e.g., sample management, imaging platforms). With more than 30 years of experience, the clinical research activity of CLB is also based on strong interaction with basic research and transfer teams. Clinical research at CLB has been ISO 9001 certified since 2013, a recognized standard for a high-level of quality and safety in the activity.




About TriNetX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, visit TriNetX at or follow @TriNetX on Twitter.


About Centre Léon Bérard (CLB), a Comprehensive Cancer Center

Centre Léon Bérard is a member of the Unicancer network, which brings together 18 French Cancer Centers and one affiliated organization. It is recognized as a regional, national, and international center of reference in oncology.

Based in Lyon, France’s second-largest metropolis, CLB performs a triple mission of care, research, and education, with the constant objective to increase the quality and accessibility of care for cancer patients.

It offers on a single site all diagnostic examinations, treatments, and follow-up of the patient during and after the illness. It welcomes more than 44,000 patients each year for hospitalization, consultation or for an examination and 6,000 new tumors are diagnosed. The Center has more than 2,000 employees, including 280 doctors, 500 researchers and 800 caregivers.

The care-research continuum is a strength of Centre Léon Bérard. On its site, doctors and researchers work in close collaboration to shorten the time between laboratory discoveries and their application to patients. Thus, each year, more than 2,000 patients are included in one of the 300 clinical trials open for inclusion.

For more information, visit Centre Léon Bérard at or follow @CLCCLeonBerard on Twitter.


Media Contacts

Centre Léon Bérard (CLB)
Nathalie BLANC
+33 (0) 4-78-78-51-43

TriNetX, LLC

Bill Stetson
+1 (857) 285-6038